Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC JH-RE-06 | 1361227-90-8 | 99.9% | 468.72 | C20H16Cl3N3O4 | 5MG
Supplier: Medchemexpress LLC HY1262145MG
JH-RE-06 is a small-molecule REV1-REV7 interface inhibitor that disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of POLζ, sensitizing cells to DNA-damaging chemotherapy. It is characterized in cellular and in vivo models for enhancing cisplatin efficacy and reducing therapy-induced mutagenesis; intended for research use only.
- Targets REV1-REV7 interface to inhibit TLS.
- Sensitizes tumor cells to DNA-damaging agents.
- Demonstrated activity in cellular and in vivo models.
- High purity suitable for biochemical and cell-based studies.
- Soluble in DMSO; available as solid and DMSO solution formats.
- Intended for research use only; not for human or clinical use.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?